John Aspegren - Publications

Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer.

Journal: Prostate cancer and prostatic diseases

Published: June 08, 2023

Pregabalin Alleviates Anxiety and Fear in Cats during Transportation and Veterinary Visits-A Clinical Field Study.

Journal: Animals : an open access journal from MDPI

Published: October 31, 2022

Nanoparticle-based oral formulation can surprise you with inferior in vivo absorption in humans.

Journal: European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V

Published: March 18, 2022

Tasipimidine-the pharmacological profile of a novel orally active selective α2A-adrenoceptor agonist.

Journal: European journal of pharmacology

Published: March 09, 2022

Efficacy of a Single Dose of Pregabalin on Signs of Anxiety in Cats During Transportation-A Pilot Study.

Journal: Frontiers in veterinary science

Published: May 19, 2021

Dexmedetomidine oromucosal gel reduces fear and anxiety in dogs during veterinary visits: A randomised, double-blind, placebo-controlled clinical pilot study.

Journal: The Veterinary record

Published: January 13, 2021

Use of Detomidine Oromucosal Gel for Alleviation of Acute Anxiety and Fear in Horses: A Pilot Study.

Journal: Frontiers in veterinary science

Published: June 16, 2020

First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours.

Journal: British journal of cancer

Published: April 08, 2020

Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Castration-resistant, CYP17 Inhibitor-naïve Prostate Cancer: Results from Extended Follow-up of the ARADES Trial.

Journal: European urology focus

Published: November 17, 2016

Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Chemotherapy-naïve and CYP17 Inhibitor-naïve Patients: Follow-up from the ARADES and ARAFOR Trials.

Journal: European urology focus

Published: November 17, 2016

Bone Scan Index and Progression-free Survival Data for Progressive Metastatic Castration-resistant Prostate Cancer Patients Who Received ODM-201 in the ARADES Multicentre Study.

Journal: European urology focus

Published: September 30, 2015

Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.

Journal: The Lancet. Oncology

Published: June 30, 2014